Pierre Fabre’s Braftovi gains CHMP positive opinion for mCRC
The recommendation covers the use of the therapy in combination with cetuximab and Folfox as a first-line treatment option for adult patients with BRAFV600E-mutant mCRC. This represents a
Autobahn Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for elunetirom, its lead central nervous system (CNS)-directed thyroid hormone receptor agonist.
The collaboration aims to accelerate hit identification for these companies through a fee-for-success approach. It will combine OpenBench’s AI-based discovery platform with Concept Life Sciences’ expertise in medicinal
Helicons are stabilised, cell-penetrant alpha-helical peptides engineered to interact with intracellular protein targets, including those with flat surfaces unsuitable for traditional small molecule engagement. The partnership will investigate